CANCER
1PMPyU0
1PMPyU0
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Bloodwise 37<br />
STRATEGIC REPORT<br />
RESEARCH INVESTMENT IN FY15:<br />
BY BLOOD <strong>CANCER</strong> TYPE<br />
Our understanding of the biology of blood cancers<br />
means that we understand the control mechanisms<br />
that must be disrupted for cancer to take hold. This<br />
means that what we learn for one blood cancer can be<br />
relevant to many others – and many other cancers too.<br />
So in some respects it’s hard to divide our research<br />
portfolio by blood cancer type. However we know<br />
that many people like to check for investment in<br />
their particular blood cancer, so this chart gives a<br />
rough guide to the primary focus areas of our new<br />
commitments made this year.<br />
COMMITMENTS FY15<br />
COMMITMENTS FY14<br />
4%4%<br />
Leukaemia<br />
12%<br />
27%<br />
12%<br />
Multi (including TAP)<br />
Lymphoma<br />
11%<br />
8% 5% 51%<br />
20%<br />
MDS & MPN<br />
Children’s blood cancers<br />
37%<br />
9%<br />
Myeloma<br />
PATIENT EXPERIENCE<br />
We’ve increased our expenditure on patient activities<br />
this year by 84% to £1.5 million (FY14: £0.8 million).<br />
This has included the establishment of a patient<br />
services team to inform and engage patients; the<br />
revision and renewal of a number of our patient<br />
information booklets; and our patient need research.<br />
As we establish our patient services directorate, do<br />
more to improve the lives of patients and respond to<br />
our patient need research findings over the coming<br />
years this investment will continue to grow.<br />
Bloodwise trading as Leukaemia & Lymphoma Research Company limited by guarantee 738089<br />
Registered charity 216032 (England & Wales) SC037529 (Scotland)
Change language